Eric P Winer

Eric P Winer

UNVERIFIED PROFILE

Are you Eric P Winer?   Register this Author

Register author
Eric P Winer

Eric P Winer

Publications by authors named "Eric P Winer"

Are you Eric P Winer?   Register this Author

100Publications

4439Reads

23Profile Views

Reply to A.K. Goel et al.

J Clin Oncol 2019 Nov 13;37(31):2954-2955. Epub 2019 Sep 13.

Sara M. Tolaney, MD, MPH and Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01822DOI Listing
November 2019

Adjuvant chemotherapy for older patients with breast cancer:  When is the pain worth the gain?

J Natl Cancer Inst 2019 Oct 15. Epub 2019 Oct 15.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz192DOI Listing
October 2019

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.

Breast Cancer Res Treat 2019 Sep 20. Epub 2019 Sep 20.

Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05445-zDOI Listing
September 2019

Aggressive Subsets of Metastatic Triple Negative Breast Cancer.

Clin Breast Cancer 2019 Jul 31. Epub 2019 Jul 31.

Department of Medicine, Ohio State University College of Medicine, Columbus, OH; Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.06.012DOI Listing
July 2019

Breast Cancer Treatment.

JAMA 2019 01;321(3):316

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.20
Publisher Site
http://dx.doi.org/10.1001/jama.2018.20751DOI Listing
January 2019

Breast Cancer Treatment: A Review.

JAMA 2019 Jan;321(3):288-300

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.19323DOI Listing
January 2019

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

N Engl J Med 2018 11 20;379(22):2108-2121. Epub 2018 Oct 20.

From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) - both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre (C.H.B.), and the University of São Paulo, São Paulo (R.H.) - both in Brazil; Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); the Department of Medical Oncology, Institut Curie, Paris (V.D.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Florida Cancer Specialists and Research Institute, New Port Richey (G.S.W.); Roche, Basel, Switzerland (V.H., A.H.); Dana-Farber Cancer Institute, Boston (E.P.W.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S.L.); and the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore (L.A.E.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809615
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809615DOI Listing
November 2018

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(26):2736-2740. Epub 2018 Jun 25.

Sharon H. Giordano, The University of Texas MD Anderson, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Ian E. Krop, Nancy U. Lin, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Jennifer Levinson, Ponte Vedra Beach; Naren Ramakrishna, Orlando Health University of Florida Health Cancer Center, Orlando, FL; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2697DOI Listing
September 2018

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

J Clin Oncol 2018 09 25;36(27):2804-2807. Epub 2018 Jun 25.

Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando; Jennifer Levinson, Ponte Vedra Beach, FL; Sarah Temin, American Society of Clinical Oncology, Alexandria, VA; Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center; Francisco J. Esteva, New York University Langone Medical Center, New York; Jeffrey J. Kirshner, Hematology/Oncology Associates of Central New York, East Syracuse, NY; Jennie R. Crews, Seattle Cancer Care Alliance, Seattle, WA; Nancy E. Davidson, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Sharon H. Giordano, University of Texas MD Anderson Cancer Center, Houston; Debra A. Patt, Texas Oncology, Austin, TX; Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; and Jane Perlmutter, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.2713DOI Listing
September 2018

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

N Engl J Med 2018 Jul 4;379(2):122-137. Epub 2018 Jun 4.

From the Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, and Breast Cancer Trials Australia and New Zealand, University of Newcastle, Newcastle, NSW (P.A.F.), and the University of Sydney, Sydney (A.S.C.) - all in Australia; the Institute of Oncology of Southern Switzerland, Ospedale San Giovanni, Bellinzona (O.P.), Breast Cancer St. Gallen, St. Gallen (T.R.), and the International Breast Cancer Study Group Coordinating Center (R.M., M.R.-P., B.R., A.S.C.), University Hospital Inselspital (M.R.-P.), Bern - all in Switzerland; the University of Chicago Medical Center, Chicago (G.F.F.); the University of Calgary, Calgary, AB, Canada (B.A.W.); the Division of Medical Senology, European Institute of Oncology (M.C.), and the European Institute of Oncology and International Breast Cancer Study Group (A.G.), Milan, Ospedale Papa Giovanni XXIII, Bergamo (C.T.), Azienda Socio Sanitaria Territoriale Sette Laghi-Ospedale di Circolo and Fondazione Macchi, Varese (G.P.), Medical Oncology and Cancer Prevention, IRCCS, National Cancer Institute, Aviano (F.P., S.S.), the Department of Medicine, School of Medical Oncology, University of Udine, Udine (F.P.), Salvatore Maugeri Foundation, Pavia (L.P.), and the Hospital of Prato-Azienda Unità Sanitaria Locale Toscana Centro, Prato (A.D.L.) - all in Italy; the National Institute of Oncology, Budapest, Hungary (I.L.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.); University Hospital 12 de Octubre, Madrid (E.C.), Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (M.B.), and Instituto Valenciano de Oncologia, Valencia (M.A.C.) - all in Spain; the Susan F. Smith Center for Women's Cancers (H.J.B., E.P.W.) and the International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology (R.D.G., M.M.R.), Dana-Farber Cancer Institute, Harvard Medical School, the Harvard T.H. Chan School of Public Health, and Frontier Science and Technology Research Foundation (R.D.G.) - all in Boston; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France (H.R.B., M.D.); the Angeles Clinic and Research Institute, Santa Monica, CA (S.M.); Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond (C.E.G.); Mayo Clinic, Rochester, MN (M.P.G., J.N.I.); Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (V.S.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (N.E.D.); Weston Park Hospital, Sheffield, United Kingdom (R.C.); and the Department of Obstetrics and Gynecology, University Medical Center, Regensburg, Germany (S.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1803164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193457PMC
July 2018

CDK4/6 inhibition in breast cancer: current practice and future directions.

Ther Adv Med Oncol 2018 17;10:1758835918786451. Epub 2018 Jul 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918786451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050811PMC
July 2018

Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.

J Natl Cancer Inst 2018 05;110(5):443-445

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article/110/5/443/4718502
Publisher Site
http://dx.doi.org/10.1093/jnci/djx264DOI Listing
May 2018

Breast cancer-specific survival by age: Worse outcomes for the oldest patients.

Cancer 2018 05 2;124(10):2184-2191. Epub 2018 Mar 2.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31308DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935594PMC
May 2018

Predicting breast cancer therapeutic response.

Nat Med 2018 05;24(5):535-537

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-018-0033-7DOI Listing
May 2018

Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.

Breast Cancer Res Treat 2018 Apr 13;168(3):727-737. Epub 2018 Jan 13.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-4659-4DOI Listing
April 2018

Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?

Clin Cancer Res 2018 04 6;24(8):1795-1804. Epub 2018 Feb 6.

Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-3351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899637PMC
April 2018

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2018 02 3;36(6):543-553. Epub 2018 Jan 3.

Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E. Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin, Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston; Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed, Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of Technology; and J. Christopher Love, Massachusetts Institute of Technology, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815405PMC
February 2018

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

Cancer Cell 2018 02;33(2):173-186.e5

Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02210, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02210, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813700PMC
February 2018

Breast cancer: T-DM1 - an important agent in the history of breast cancer management.

Nat Rev Clin Oncol 2017 11 8;14(11):651-652. Epub 2017 Aug 8.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.123DOI Listing
November 2017

Reply to S. Sorscher.

J Clin Oncol 2017 05 6;35(15):1746-1747. Epub 2017 Mar 6.

Brent S. Rose, University of California San Diego, San Diego, CA; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; and Harvey J. Mamon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.2876DOI Listing
May 2017

Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?

J Natl Cancer Inst 2017 Apr;109(4)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw316DOI Listing
April 2017

Surveillance Mammography in Older Patients With Breast Cancer-Can We Ever Stop?: A Review.

JAMA Oncol 2017 Mar;3(3):402-409

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.3931DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540165PMC
March 2017

Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.

J Natl Compr Canc Netw 2017 03;15(3):316-324

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2017.0031DOI Listing
March 2017

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

J Clin Oncol 2017 Feb 19;35(4):421-431. Epub 2016 Dec 19.

Rachel A. Freedman, Eric P. Winer, and Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Jared C. Foster, Drew K. Seisler, Jacqueline M. Lafky, and Aminah Jatoi, Mayo Clinic; Jared C. Foster and Drew K. Seisler, Mayo Cancer Center, Rochester, MN; Hyman B. Muss and Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Harvey J. Cohen, Constance Cirrincione, and Gretchen Kimmick, Duke University, Durham, NC; Jeanne Mandelblatt, Georgetown University, Washington, DC; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; Alvaro Moreno-Aspitia, Mayo Clinic, Jacksonville, FL; and Arti Hurria, City of Hope, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455700PMC
February 2017

Perils of the Pathologic Complete Response.

J Clin Oncol 2016 11 31;34(33):3959-3962. Epub 2016 Oct 31.

Brent S. Rose, Harvard Radiation Oncology Program, Boston, MA; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; and Harvey J. Mamon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1718DOI Listing
November 2016

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.

Breast Cancer Res Treat 2016 11 6;160(2):305-312. Epub 2016 Oct 6.

Department of Medical Oncology, Breast Oncology Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4001-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065609PMC
November 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.

J Clin Oncol 2016 09 1;34(27):3308-14. Epub 2016 Aug 1.

Ann H. Partridge, Melissa E. Hughes, Erica T. Warner, Eric P. Winer, Jane C. Weeks, and Rulla M. Tamimi, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Erica T. Warner, Harvard T.H. Chan School of Public Health, Boston, MA; Rebecca A. Ottesen and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte; and Douglas W. Blayney, Stanford Cancer Institute, Palo Alto, CA; Yu-Ning Wong, Fox Chase Cancer Center, Philadelphia, PA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Richard L. Theriault, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.8013DOI Listing
September 2016

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

J Clin Oncol 2016 08 2;34(22):2602-9. Epub 2016 May 2.

Maura N. Dickler, Mary Ellen Moynahan, Diana E. Lake, and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; William T. Barry, Dana-Farber Cancer Institute; Eric P. Winer, Dana-Farber/Partners Cancer Care, Boston, MA; Constance T. Cirrincione, Duke University, Durham, NC; Matthew J. Ellis, Baylor College of Medicine; Debasish Tripathy, The University of Texas MD Anderson Cancer Center, Houston, TX; Federico Innocenti and Lisa A. Carey, University of North Carolina at Chapel Hill, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte; Hope S. Rugo, University of California at San Francisco, San Francisco, CA; Olwen Hahn, Alliance for Clinical Trials in Oncology, Chicago, IL; and Bryan P. Schneider, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690PMC
August 2016

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab.

Breast Cancer Res Treat 2016 08 2;159(1):151-62. Epub 2016 Aug 2.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3927-4DOI Listing
August 2016

I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.

N Engl J Med 2016 Jul;375(1):83-4

From the Division of Hematology-Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (L.A.C.); and the Breast Oncology Program, Dana-Farber Cancer Institute, Boston (E.P.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1603691DOI Listing
July 2016

Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.

Breast Cancer Res Treat 2016 06 6;157(3):587-96. Epub 2016 Jun 6.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-3845-5DOI Listing
June 2016

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

J Clin Oncol 2016 05 16;34(14):1689-701. Epub 2016 Feb 16.

Harold J. Burstein and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Christina Lacchetti, American Society of Clinical Oncology, Alexandria, VA; Holly Anderson, Breast Cancer Coalition of Rochester, Rochester, NY; Thomas A. Buchholz and Sharon H. Giordano, The University of Texas MD Anderson Cancer Center, Houston, TX; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA; Karen E. Gelmon, British Columbia Cancer Agency, Vancouver, BC; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Alexander J. Solky, Interlakes Oncology and Hematology PC, Rochester, NY; Vered Stearns, Johns Hopkins, Baltimore, MD; and Jennifer J. Griggs, University of Michigan, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.9573DOI Listing
May 2016

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.

J Clin Oncol 2016 May 14;34(13):1460-8. Epub 2016 Mar 14.

Nadine Tung, Beth Israel Deaconess Medical Center; Nancy U. Lin, Eric P. Winer, and Judy E. Garber, Dana-Farber Cancer Institute; Nadine Tung, Nancy U. Lin, Eric P. Winer, and Judy E. Garber, Harvard Medical School, Boston, MA; and John Kidd, Brian A. Allen, Nanda Singh, Richard J. Wenstrup, and Anne-Renee Hartman, Myriad Genetic Laboratories, Inc., Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872307PMC
May 2016

Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Cancer 2016 Apr 12;122(8):1169-77. Epub 2016 Feb 12.

Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29899DOI Listing
April 2016

Timeliness in Breast Cancer Treatment-The Sooner, the Better.

JAMA Oncol 2016 Mar;2(3):302-4

Department of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4506DOI Listing
March 2016

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

J Clin Oncol 2016 Mar 1;34(9):945-52. Epub 2016 Feb 1.

Rachel A. Freedman, Rebecca S. Gelman, Christina Herold, Nicole Ryabin, Sarah Farooq, Elizabeth Lawler, Ian E. Krop, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital; Alarice Lowe and Nathalie Y.R. Agar, Brigham and Women's Hospital, Boston, MA; Jeffrey S. Wefel, Kenneth R. Hess, and Nuhad Ibrahim, The University of Texas MD Anderson Cancer Center; Polly A. Niravath and Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; Michelle E. Melisko, University of California, San Francisco, San Francisco, CA; Roisin M. Connolly and Antonio C. Wolff, Johns Hopkins University, Baltimore, MD; Catherine H. Van Poznak, University of Michigan, Ann Arbor, MI; Shannon L. Puhalla, University of Pittsburgh Cancer Institute and Magee-Women's Hospital, Pittsburgh, PA; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; and Minetta C. Liu, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2016/01/28/JCO.2015.63
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.0343
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.0343DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070554PMC
March 2016

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Cancer Cell 2016 Mar;29(3):255-269

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.02.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794996PMC
March 2016

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

J Clin Oncol 2016 Feb 2;34(6):542-9. Epub 2015 Nov 2.

Lisa A. Carey, David W. Ollila, Carey K. Anders, Katherine A. Hoadley, Michael Iglesia, and Charles M. Perou, University of North Carolina Chapel Hill, Chapel Hill; Constance T. Cirrincione and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Donald A. Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Ian E. Krop and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Lyndsay N. Harris, University Hospitals of Cleveland, Cleveland, OH; Norah Lynn Henry, University of Michigan, Ann Arbor, MI; Douglas J. Weckstein, New Hampshire Hematology-Oncology, Hooksett, NH; Baljit Singh, New York University; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Maggie Chon U. Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567PMC
February 2016

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.

Breast 2015 Nov 5;24 Suppl 2:S132-5. Epub 2015 Aug 5.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.032DOI Listing
November 2015

POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.

Oncology (Williston Park) 2015 Nov;29(11):797-8, 802

View Article

Download full-text PDF

Source
November 2015

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

J Clin Oncol 2015 Sep 27;33(25):2772-9. Epub 2015 Jul 27.

Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.60.8133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550691PMC
September 2015

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Authors:
Ayalew Tefferi Hagop Kantarjian S Vincent Rajkumar Lawrence H Baker Jan L Abkowitz John W Adamson Ranjana Hira Advani James Allison Karen H Antman Robert C Bast John M Bennett Edward J Benz Nancy Berliner Joseph Bertino Ravi Bhatia Smita Bhatia Deepa Bhojwani Charles D Blanke Clara D Bloomfield Linda Bosserman Hal E Broxmeyer John C Byrd Fernando Cabanillas George Peter Canellos Bruce A Chabner Asher Chanan-Khan Bruce Cheson Bayard Clarkson Susan L Cohn Gerardo Colon-Otero Jorge Cortes Steven Coutre Massimo Cristofanilli Walter J Curran George Q Daley Daniel J DeAngelo H Joachim Deeg Lawrence H Einhorn Harry P Erba Francisco J Esteva Elihu Estey Isaiah J Fidler James Foran Stephen Forman Emil Freireich Charles Fuchs James N George Morie A Gertz Sergio Giralt Harvey Golomb Peter Greenberg Jordan Gutterman Robert I Handin Samuel Hellman Paulo Marcelo Hoff Ronald Hoffman Waun Ki Hong Mary Horowitz Gabriel N Hortobagyi Clifford Hudis Jean Pierre Issa Bruce Evan Johnson Philip W Kantoff Kenneth Kaushansky David Khayat Fadlo R Khuri Thomas J Kipps Margaret Kripke Robert A Kyle Richard A Larson Theodore S Lawrence Ross Levine Michael P Link Scott M Lippman Sagar Lonial Gary H Lyman Maurie Markman John Mendelsohn Neal J Meropol Yoav Messinger Therese M Mulvey Susan O'Brien Roman Perez-Soler Raphael Pollock Josef Prchal Oliver Press Jerald Radich Kanti Rai Saul A Rosenberg Jacob M Rowe Hope Rugo Carolyn D Runowicz Brenda M Sandmaier Alan Saven Andrew I Schafer Charles Schiffer Mikkael A Sekeres Richard T Silver Lillian L Siu David P Steensma F Marc Stewart Wendy Stock Richard Stone Rainer Storb Louise C Strong Martin S Tallman Michael Thompson Naoto T Ueno Richard A Van Etten Julie M Vose Peter H Wiernik Eric P Winer Anas Younes Andrew D Zelenetz Charles A LeMaistre

Mayo Clin Proc 2015 Aug 23;90(8):996-1000. Epub 2015 Jul 23.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mayocp.2015.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365030PMC
August 2015

Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.

J Clin Oncol 2015 Jul 11;33(20):2254-61. Epub 2015 May 11.

Erica T. Warner and Rulla M. Tamimi, Harvard School of Public Health; Erica T. Warner, Rulla M. Tamimi, Melissa E. Hughes, Eric P. Winer, Jane C. Weeks, and Ann H. Partridge, Brigham and Women's Hospital; Melissa E. Hughes, Eric P. Winer, Jane C. Weeks, and Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Rebecca A. Ottesen and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte; Douglas W. Blayney, Stanford University Cancer Center, Palo Alto, CA; Yu-Ning Wong, Fox Chase Cancer Center, Philadelphia, PA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.1349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486344PMC
July 2015

Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women.

Oncologist 2015 Jul 29;20(7):713-8. Epub 2015 May 29.

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA; University Hospitals Case Medical Center, Cleveland, Ohio, USA; Harvard Medical School, Boston, Massachusetts, USA; Mayo Clinic, Rochester, Minnesota, USA; Massachusetts General Hospital, Boston, Massachusetts, USA; University of Colorado Cancer Center, Aurora, Colorado, USA; Oregon Health & Science University, Portland, Oregon, USA; Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492229PMC
July 2015

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

J Clin Oncol 2015 Jul 8;33(21):2361-9. Epub 2015 Jun 8.

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Erica L. Mayer and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Alvaro Moreno-Aspitia and Edith A. Perez, Mayo Clinic, Jacksonville, FL; Alan P. Lyss, Heartland Cancer Research Community Clinical Oncology Program; Michael Naughton, Washington University School of Medicine, St Louis, MO; Constance Cirrincione and Eleanor Leung, Alliance Statistics and Data Center, Duke University, Durham; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Deborah Toppmeyer, Cancer Institute of New Jersey, New Brunswick, NJ; and Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830PMC
July 2015

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2015 Jun 6;33(17):1902-9. Epub 2015 Apr 6.

Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.6660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451173PMC
June 2015

Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.

Breast Cancer Res Treat 2015 Jun 29;151(3):697-707. Epub 2015 May 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3432-1DOI Listing
June 2015

Tumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancer.

J Clin Oncol 2015 Mar 5;33(9):969-71. Epub 2015 Jan 5.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.6031DOI Listing
March 2015

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

J Clin Oncol 2015 Mar 20;33(7):701-8. Epub 2015 Jan 20.

Edith A. Perez, E. Aubrey Thompson, Yan W. Asmann, and Xochiquetzal J. Geiger, Mayo Clinic, Jacksonville, FL; Karla V. Ballman, S. Keith Anderson, Krishna R. Kalari, Jeanette E. Eckel-Passow, Kathleen S. Tenner, Jin Jen, Beiyun Chen, Robert B. Jenkins, and Monica M. Reinholz, Mayo Clinic, Rochester, MN; Amylou C. Dueck, and Ann E. McCullough, Mayo Clinic, Scottsdale, AZ; Jian-Bing Fan, Illumina, San Diego, CA; George W. Sledge, Stanford School of Medicine, Palo Alto, CA; Eric P. Winer, Harvard Medical School, Boston, MA; and Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.6298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334774PMC
March 2015

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

J Natl Cancer Inst 2015 Mar 16;107(3). Epub 2015 Feb 16.

Departments of Breast Medical Oncology (AMGA, SL, SMT), Systems Biology (AMGA, GBM), Biostatistics (HC, YL, K-AD), Experimental Therapeutics (KSC), Investigational Cancer Therapeutics (AA, ET, SPP, VV-B, FMB), Pathology (AAS) and Surgical Oncology (FMB), The University of Texas MD Anderson Cancer Center, Houston, TX; Division of Hematology-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (IK, EPW); Division of Hematology-Oncology, University of California, San Diego, CA (RK); Cancer Therapy Evaluation Program, NIH/National Cancer Institute, Rockville, MD (LAD).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/dju493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342675PMC
March 2015

Reply to V. Amoroso et al.

J Clin Oncol 2015 Jan 15;33(3):291. Epub 2014 Dec 15.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.1875DOI Listing
January 2015

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

N Engl J Med 2015 Jan;372(2):134-41

From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867PMC
January 2015